Clinical efficacy and short-term prognosis of butylphthalide sodium chloride injection combined with edaravone dextroborneol in acute stroke

Stroke is one of the important causes of death of patients. Both butylphthalide sodium chloride injection (BSCI) and edaravone dextroborneol (ED) show a curative effect. We intend to assess their effect on acute stroke. Patients with acute ischemic stroke diagnosed by our hospital in the past were included as research objects and different treatment methods were used to divide them into different groups. The research group was given combined treatment (BSCI and ED). The normal group chose one of the drugs as treatment. The curative effect was recorded. The neurological deficit score, the commonly used clinical infection markers mainly include IL-6, CRP and TNF-α, and the Barthel index widely used in the field of rehabilitation and elderly patients, hemorheology index and the expression of NSE were evaluated. The changes before and after medical level were compared with the adverse reaction group during the treatment. The analysis of Barthel index reflected that the effective rate was higher than normal group. Changes in neural functions were decreased than normal group (P <0.05) and the adverse reactions in the curing process were lower in both groups, but there was no statistical difference (P >0.05). Our research shows that combined therapy can improve drug efficacy by reducing the expression of cytokines and it does not bring about an increase in toxic and side effects. Combination therapy improves neurological function, reduces cytokine secretion, improves drug efficacy, and has a high drug safety.